Skip navigation
MedlinePlus Trusted Health Information for You U.S. National Library of MedicineNational Institutes of Health
Contact Us FAQs Site Map About MedlinePlus
español Home Health Topics Drug Information Medical Encyclopedia Dictionary News Directories Other Resources

Breast cancer drug cuts prostate cancer

Printer-friendly version E-mail this page to a friend
United Press International

Tuesday, October 19, 2004

SEATTLE, Oct 19, 2004 (United Press International via COMTEX) -- The drug toremifene, used to treat breast cancer in women, has been found to also reduce the incidence of prostate cancer in men at risk for the disease.

The study found patients at all dose levels of toremifene had a lower cumulative incidence of prostate cancer after 12 months of treatment, with the 20 mg dose contributing the greatest effect.

All participating patients had high-grade prostatic intraepithelial neoplasia, known as PIN, characterized by abnormal cells in the lining of the prostate ducts. Research suggests most patients with high-grade PIN will develop prostate cancer within 10 years, however more research is needed to confirm those findings, the researchers said.

"For men with high-grade PIN, the prospect of developing prostate cancer is a very real possibility," said Dr. Mitchell Steiner, chief executive officer with GTx, Inc., a biopharmaceutical company dedicated to the treatment of serious men's health conditions.

The study was presented Tuesday during the American Association for Cancer Research Third Annual International Conference on Frontiers in Cancer Prevention Research in Seattle.



Copyright 2004 by United Press International.

Related News:
More News on this Date

Related MedlinePlus Pages: